Inactive

The National Institute on Drug Abuse invites you to submit a proposal responding to the requirements of this RFP No. 75N95023R00019 titled “Toxicological Evaluations of Potential Medications ". For mo... The National Institute on Drug Abuse invites you to submit a proposal responding to the requirements of this RFP No. 75N95023R00019 titled “Toxicological Evaluations of Potential Medications ". For more details please see the attached RFP.

Inactive

This is a SMALL BUSINESS SOURCES SOUGHT NOTICE to determine the availability of ALL small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZo... This is a SMALL BUSINESS SOURCES SOUGHT NOTICE to determine the availability of ALL small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, women-owned small businesses, and other small businesses) to fulfill the needs of NIH and NIDA for this future requirement. The NIDA Medications Discovery and Toxicology Branch has the mission to facilitate, through preclinical medications discovery and safety assessment efforts, the translation of basic research findings into pharmacotherapies for the treatment of substance use disorders. When preclinical development candidates are identified, this contract provides a resource for the development of safety data that support filing Investigational New Drug (IND) applications and New Drug Application(s) (NDA) to the U.S. Food and Drug Administration (FDA). In this context, the primary objective of this research and development contract is to support preclinical safety pharmacology studies and preclinical acute and repeat dose toxicology studies in rodents, rabbits, dogs and/or nonhuman primates (monkeys) on test articles that are potential pharmacotherapies (medications) to treat substance use disorders. It is anticipated that NIDA will use the results of these preclinical studies in IND and NDA filings with the FDA in accordance with FDA Guidances, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines and Good Laboratory Practice for Nonclinical Laboratory Studies (GLP) regulations. Please see the attachment for more details.